Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 8 uM | Compound was evaluated for inhibition of expression of VCAM-1 in IL-1 beta activated human umbilical vein endothelial cells(HUVECs) by using ELISA | ChEMBL. | No reference |
IC50 (functional) | = 8 uM | Compound was evaluated for inhibition of expression of VCAM-1 in IL-1 beta activated human umbilical vein endothelial cells(HUVECs) by using ELISA | ChEMBL. | No reference |
IC50 (functional) | = 10 uM | Compound was evaluated for inhibition of expression of ELAM-1 in IL-1 beta activated human umbilical vein endothelial cells(HUVECs) by using ELISA | ChEMBL. | No reference |
IC50 (functional) | = 10 uM | Compound was evaluated for inhibition of expression of ELAM-1 in IL-1 beta activated human umbilical vein endothelial cells(HUVECs) by using ELISA | ChEMBL. | No reference |
Inhibition (functional) | = 55 % | Compound was evaluated for inhibition of neutrophil recruitment in a mouse skin immune complex model. | ChEMBL. | No reference |
Inhibition (functional) | = 55 % | Compound was evaluated for inhibition of neutrophil recruitment in a mouse skin immune complex model. | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.